HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) will release its second quarter 2022 financial results and company update on August 11, 2022, prior to market opening. The company, focused on immunotherapies using its proprietary arenavirus platform, aims to mobilize targeted T cells to combat serious diseases. Its pipeline includes investigational therapies for HPV16+ cancers, prostate cancer, KRAS-mutated cancers, and efforts to develop functional cures for HBV and HIV in collaboration with Gilead. No conference call is scheduled for this earnings release.

Positive

• Ongoing development of innovative immunotherapies targeting various cancers.
• Collaboration with Gilead to develop functional cures for HBV and HIV.

Negative

• None.

NEW YORK and VIENNA, Austria, Aug. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it will release its second quarter 2022 financial results and Company update before the market open on Thursday, August 11, 2022.

The Company will not be conducting a conference call in conjunction with this earnings release.

About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:
Media	Investors
Michael Szumera	Matt Beck
Executive Director - Communications	Executive Director - Investor Relations
michael.szumera@hookipapharma.com	matthew.beck@hookipapharma.com
+1 917 561 8905	+1 917 209 6886

FAQ

When will HOOKIPA release its Q2 2022 financial results?

HOOKIPA will release its second quarter 2022 financial results on August 11, 2022.

What is HOOKIPA focusing on in its drug development?

HOOKIPA focuses on developing novel immunotherapies using its proprietary arenavirus platform to target cancers and other serious diseases.

Will HOOKIPA conduct a conference call after its earnings release?

No, HOOKIPA will not conduct a conference call in conjunction with its earnings release.

What types of cancers is HOOKIPA targeting with its therapies?

HOOKIPA is targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers, including colorectal, pancreatic, and lung cancers.

Who is HOOKIPA collaborating with for HBV and HIV development?

HOOKIPA is collaborating with Gilead to develop functional cures for HBV and HIV.